Company intelligence / Profile preview
Trillium Therapeutics Inc.
Mississauga, Ontario, Canadatrilliumtherapeutics.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
Trillium's lead molecules TTI-622 and TTI-621 showed promising clinical activity in Phase 1 trials for relapsed/refractory lymphomas, with TTI-622 demonstrating a 33% overall response rate at doses of 0.8-18 mg/kg and TTI-621 showing 18-29% overall response rate at up to 2.0 mg/kg. Deep and durable responses were observed in heavily pretreated patients with advanced DLBCL[9].
- Therapeutic areas
- Oncology
- Modalities
- BiologicsSIRPα-Fc fusion proteinssmall molecule STING agonists
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Pfizer (initially invested $25 million in September 2020 before acquisition)
Beyond the preview
Go deeper on Trillium Therapeutics Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Trillium Therapeutics Inc..